SUNNYVALE, Calif., Aug. 17, 2017 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) and the Summit Cancer Center-Boise
announced today that the Center is now treating patients with the
Radixact™ Treatment Delivery System, the next generation
TomoTherapy® platform. The Radixact System replaced a competitive
conventional linear accelerator in the single-vault freestanding
facility, reinforcing the System's value as a mainstream radiation
therapy device.
The Radixact System provides precise and accurate treatments for
more routine radiation therapy indications including skin, central
nervous system, breast, head and neck, lung, prostate, gynecologic,
and gastrointestinal malignancies, in addition to more complex
treatments such as craniospinal and total marrow irradiation.
Additionally, Summit Cancer Center-Boise has the ability to perform
stereotactic radiosurgery (SRS) and stereotactic body radiotherapy
(SBRT).
"At Summit Cancer Center-Boise our goal is to use innovative
technology to provide our patients with the treatment best suited
to their needs. This system allows us to provide precise,
individualized treatment while sparing normal tissues and
maintaining optimal treatment efficacy," said John E. Gamboa, MD, radiation oncologist,
medical director of Summit Cancer Center-Boise.
"We are committed to working with Dr. Gamboa to maximize the
benefits the new Radixact System provides to his patients," said
Lionel Hadjadjeba, Senior Vice President and Chief Commercial
Officer at Accuray. "As the recent TomoTherapy System vs RapidArc
study published in the Red Journal demonstrated, the
technique used to deliver IMRT can have a major impact on patient
outcomes. The Radixact System leverages the TomoTherapy platform's
unique helical delivery and is equipped with the tools and
technology Dr. Gamboa will need to effectively and efficiently
treat any cancer case he and his team may encounter, from initial
plan delivery to adaptive therapy to complex retreatments."
Radixact System Overview
The use of radiation as part of cancer treatment is increasing,
both during initial treatment and increasingly for re-treatment, so
the ability to deliver the correct dose precisely to the tumor is
becoming even more important. The Radixact System was designed to
deliver image-guided intensity-modulated radiation therapy, an
extremely precise form of radiation therapy.
- The System is built on a ring gantry platform with a CT
scanner. It provides continuous delivery of radiation from 360
degrees around the patient, or delivery from clinician-specified
beam angles, ensuring the most precise treatment customized for
each patient, minimizing exposure to healthy tissue and measurably
mitigating side effects.
- Treatment accuracy is achieved through daily 3D image guidance
which ensures proper patient positioning and dose targeting even
when anatomical changes occur. The system takes an image of the
patient every day as part of the patient setup, enabling the
clinical team to know exactly where the tumor is on that particular
day.
- The ultra-fast binary multileaf collimator, or MLC, is a key
component of the System, enabling the System to deliver dose with
extremely high precision and accuracy.
- Continuous couch motion through the bore of the ring gantry
facilitates seamless delivery to multiple targets or long volumes
with no need for field matching, which would be required if using a
conventional delivery device. This innovation in workflow also
improves treatment quality by ensuring that highly-sculpted
radiation doses can be delivered to tumors located anywhere in the
body, regardless of the tumor size or the number of tumors
receiving treatment.
- A fully-integrated, simplified adaptive treatment planning
solution, PreciseART™ Adaptive Radiation Therapy software, enables
the clinical team to adjust therapy to changes in tumor size, shape
and location — as well as subtle changes in the location of organs
and other healthy tissue.
- The PreciseRTX™ Retreatment Option makes it easier for
clinicians to deliver precise doses of radiation in those cases
where, unfortunately, cancer has recurred and retreatment with
radiation is necessary.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to advantages of new
technology, clinical applications, clinical results, successful
adoption of new technologies, patient experiences and outcomes, and
Accuray's leadership position in radiation oncology innovation and
technologies. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from expectations, including but not limited to the risks detailed
from time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016, February 3, 2017, and May
5, 2017, and as updated periodically with the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Doug Sherk
EVC Group
+1 (646) 445-4800
dsherk@evcgroup.com
Media Contacts:
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSL Group
+1 (781) 684-0770
accuray@mslgroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/summit-cancer-center-boise-treats-its-first-cancer-patients-using-the-accuray-radixact-system-300505763.html
SOURCE Accuray Incorporated